Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (1y) (2013 - 2026)
Enanta Pharmaceuticals (ENTA) Net Cash Flow Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | 89.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.86% |
| Dec 31, 2025 | -89.09% |
| Sep 30, 2025 | -958.30% |
| Jun 30, 2025 | 44.53% |
| Mar 31, 2025 | -204.81% |
| Dec 31, 2024 | 203.65% |
| Sep 30, 2024 | 114.89% |
| Jun 30, 2024 | -226.22% |
| Mar 31, 2024 | -23.73% |
| Dec 31, 2023 | -2,466.63% |
| Sep 30, 2023 | -162.64% |
| Jun 30, 2023 | 337.52% |
| Mar 31, 2023 | 153.30% |
| Dec 31, 2022 | -104.23% |
| Sep 30, 2022 | -70.29% |
| Jun 30, 2022 | 87.23% |
| Mar 31, 2022 | -363.62% |
| Dec 31, 2021 | 230.67% |
| Sep 30, 2021 | 513.43% |
| Jun 30, 2021 | -384.22% |